최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기Journal of clinical gastroenterology, v.39 no.6, 2005년, pp.520 - 528
Ball, Karen R (From the *University of Washington (Bastyr University Visiting Scholar), and †Department of Medicine, University of Washington School of Medicine, Seattle, WA.) , Kowdley, Kris V
Silybum marianum (milk thistle) and its derivatives have been used for centuries for the treatment of liver disease. This review focuses exclusively on published literature pertaining to the potential use of Silybum marianum or its derivatives for the treatment of alcoholic liver disease. Clinical studies have varied greatly in quality, with the majority limited by inadequate sample size, lack of uniformity in the population treated, lack of standardization of preparations studied, variability in dosing regimens, inconsistent outcome measures, and lack of information on concurrent use of alcohol during the treatment period. While Silybum marianum and its derivatives appear to be safe and the available evidence on the mechanisms of action appears promising, there are currently insufficient data from well-conducted clinical trials to recommend their use in patients with alcoholic liver disease.
Evid Rep Technol Assess 21 1 2000 Milk thistle: effects on liver disease and cirrhosis and clinical adverse effects.
Fitoterapia Morazzoni LXVI 3 1995 Silybum marianum (Carduus marianus).
Altern Med Rev Luper 3 410 1998 A review of plants used in the treatment of liver disease: part 1.
Am J Health Syst Pharm Pepping 56 1195 1999 10.1093/ajhp/56.12.1195 Milk thistle: Silybum marianum.
Am J Gastroenterol Flora 93 139 1998 10.1111/j.1572-0241.1998.00139.x Milk thistle (Silybum marianum) for the therapy of liver disease.
Herbalgram Blumenthal 55 60 2002 Herb sales down in mainstream market, up in natural food stores.
Hepatology Schuppan 30 1099 1999 10.1002/hep.510300437 Herbal products for liver diseases: a therapeutic challenge for the new millennium.
Gastroenterol Nurs Giese 24 38 2001 10.1097/00001610-200101000-00010 Complementary healthcare practices.
Methods Find Exp Clin Pharmacol Lorenz 6 655 1984 Pharmacokinetic studies with silymarin in human serum and bile.
Drugs Saller 61 2035 2001 10.2165/00003495-200161140-00003 The use of silymarin in the treatment of liver diseases.
Phytother Res Zuber 16 632 2002 10.1002/ptr.1000 Effect of silybin and its congeners on human liver microsomal cytochrome P450 activities.
Int J Clin Pharmacol Weyhenmeyer 30 134 1992 Study on dose-linearity of the pharmacokinetics of silibinin diastereomers using a new stereospecific assay.
Drugs of the Future 15 226 1990 Silybin phosphatidylcholine complex.
Am J Med Jacobs 113 506 2002 10.1016/S0002-9343(02)01244-5 Milk thistle for the treatment of liver disease: a systematic review and meta-analysis.
Cell Biochem Funct Valenzuela 7 173 1989 10.1002/cbf.290070304 Effect of silybin dihemisuccinate on the ethanol metabolizing systems of the rat liver.
Br Med Bull Sherman 50 124 1994 10.1093/oxfordjournals.bmb.a072871 Liver damage: mechanisms and management.
Ann N Y Acad Sci Tuma 625 786 1991 10.1111/j.1749-6632.1991.tb33920.x Acetaldehyde and microtubules.
Biochem Biophys Res Commun Neuman 197 932 1993 10.1006/bbrc.1993.2569 In vitro assessment of the ethanol-induced hepatotoxicity on HepG2 cell line.
Alcohol Martinez 9 455 1992 10.1016/0741-8329(92)90080-T Ethanol and cytokine secretion.
Gastroenterology Neuman 115 157 1998 10.1016/S0016-5085(98)70377-4 Role of cytokines in ethanol-induced cytotoxicity in vitro in Hep G2 cells.
J Hepatol Hirano 38 483 2003 10.1016/S0168-8278(02)00456-7 Tumor necrosis factor alpha (TNF-alpha)-induced RANTES chemokine expression via activation of NF-kappaB and p38 MAP kinase: roles of TNF-alpha in alcoholic liver diseases.
Gut Mookerjee 52 1182 2003 10.1136/gut.52.8.1182 Tumour necrosis factor alpha is an important mediator of portal and systemic haemodynamic derangements in alcoholic hepatitis.
Clin Chim Acta Lieber 257 59 1997 10.1016/S0009-8981(96)06434-0 Ethanol metabolism, cirrhosis and alcoholism.
J Gastroenterol Hepatol Ishii 12 S272 1997 10.1111/j.1440-1746.1997.tb00510.x Pathogenesis of alcoholic liver disease with particular emphasis on oxidative stress.
Gut Williams 28 1157 1987 10.1136/gut.28.9.1157 Free radical generation by neutrophils: a potential mechanism of cellular injury in acute alcoholic hepatitis.
J Clin Invest Kono 106 867 2000 10.1172/JCI9020 NADPH oxidase-derived free radicals are key oxidants in alcohol-induced liver disease.
J Clin Invest Garcia-Ruiz 94 193 1994 10.1172/JCI117306 Effect of chronic ethanol feeding on glutathione and functional integrity of mitochondria in periportal and perivenous rat hepatocytes.
Alcohol Fernandez-Checa 10 469 1993 10.1016/0741-8329(93)90067-X Mitochondrial glutathione depletion in alcoholic liver disease.
Alcohol Fernandez-Checa 27 179 2002 10.1016/S0741-8329(02)00229-X S-Adenosyl-L-methionine and mitochondrial reduced glutathione depletion in alcoholic liver disease.
J Clin Invest Fernandez-Checa 87 397 1991 10.1172/JCI115010 Impaired uptake of glutathione by hepatic mitochondria from chronic ethanol-fed rats: tracer kinetic studies in vitro and in vivo and susceptibility to oxidant stress.
Gut Duguay 23 8 1982 10.1136/gut.23.1.8 Inhibition of liver regeneration by chronic alcohol administration.
Dig Dis Sci Morales-Gonzalez 46 360 2001 10.1023/A:1005613201809 Effects of ethanol administration on hepatocellular ultrastructure of regenerating liver induced by partial hepatectomy.
Alcohol Clin Exp Res Koteish 26 1710 2002 10.1111/j.1530-0277.2002.tb02475.x Ethanol induces redox-sensitive cell-cycle inhibitors and inhibits liver regeneration after partial hepatectomy.
Gastroenterology Zhang 119 1333 2000 10.1053/gast.2000.19281 Light ethanol consumption enhances liver regeneration after partial hepatectomy in rats.
Alcohol Clin Exp Res Diehl 23 1419 1999 10.1111/j.1530-0277.1999.tb04662.x Cytokines and the molecular mechanisms of alcoholic liver disease.
Alcohol Clin Exp Res Saso 20 suppl 9 330A 1996 10.1111/j.1530-0277.1996.tb01802.x Inhibitory effect of ethanol on hepatocyte growth factor-induced DNA synthesis and Ca2+ mobilization in rat hepatocytes.
Biochem Biophys Res Commun Zhang 257 89 1999 10.1006/bbrc.1999.0403 Chronic ethanol consumption disrupts complexation between EGF receptor and phospholipase C-gamma1: relevance to impaired hepatocyte proliferation.
Kidney Int Suppl Gressner 54 suppl 39 1996 Transdifferentiation of hepatic stellate cells (Ito cells) to myofibroblasts: a key event in hepatic fibrogenesis.
BMJ Burt 305 537 1992 10.1136/bmj.305.6853.537 Liver fibrosis: better understanding may help diagnosis and treatment.
J Hepatol Gressner 22 suppl 2 28 1995 Cytokines and cellular crosstalk involved in the activation of fat-storing cells.
Alcohol Clin Exp Res Enomoto 24 suppl 4 55 2000 10.1111/j.1530-0277.2000.tb00013.x Alcohol enhances lipopolysaccharide-induced increases in nitric oxide production by Kupffer cells via mechanisms dependent on endotoxin.
J Gastroenterol Hepatol Bautista 15 349 2000 10.1046/j.1440-1746.2000.02174.x Impact of alcohol on the ability of Kupffer cells to produce chemokines and its role in alcoholic liver disease.
Free Radic Biol Med Wheeler 31 1544 2001 10.1016/S0891-5849(01)00748-1 The role of Kupffer cell oxidant production in early ethanol-induced liver disease.
Toxicol Sci Jaeschke 65 166 2002 10.1093/toxsci/65.2.166 Mechanisms of hepatotoxicity.
Biochem Pharmacol Mira 48 753 1994 10.1016/0006-2952(94)90053-1 Scavenging of reactive oxygen species by silibinin dihemisuccinate.
Phytother Res Varga 15 608 2001 10.1002/ptr.879 Inhibition of the superoxide anion release and hydrogen peroxide formation in PMNLs by flavonolignans.
Hepatology Dehmlow 23 749 1996 10.1002/hep.510230415 Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibinin.
Acta Physiol Hung Muzes 78 3 1991 Effect of the bioflavonoid silymarin on the in vitro activity and expression of superoxide dismutase (SOD) enzyme.
Acta Physiol Hung Altorjay 80 375 1992 The effect of silibinin (Legalon) on the free radical scavenger mechanisms of human erythrocytes in vitro.
In: Toxic In Vitro Miguez 8 581 1994 Comparative study of the hepatoprotective effect of silymarin and silybin on isolated rat hepatocytes.
J Immunol Manna 163 6800 1999 10.4049/jimmunol.163.12.6800 Silymarin suppresses TNF-induced activation of NF-kappa B, c-Jun N-terminal kinase, and apoptosis.
FEBS Lett Saliou 440 8 1998 10.1016/S0014-5793(98)01409-4 Selective inhibition of NF-kappaB activation by the flavonoid hepatoprotector silymarin in HepG2: evidence for different activating pathways.
Int J Tissue React Meroni 10 177 1988 Silybin inhibition of human T-lymphocyte activation.
Arzneimittelforschung Fuchs 47 1383 1997 Effects of silibinin and of a synthetic analogue on isolated rat hepatic stellate cells and myofibroblasts.
Planta Med Valenzuela 55 420 1989 10.1055/s-2006-962056 Selectivity of silymarin on the increase of the glutathione content in different tissues of the rat.
Biochem Pharmacol Valenzuela 34 2209 1985 10.1016/0006-2952(85)90421-6 Silymarin protection against hepatic lipid peroxidation induced by acute ethanol intoxication in the rat.
Arzneimittelforschung Magliulo 23 suppl 161 1973 Studies on the regenerative capacity of the liver in rats subjected to partial hepatectomy and treated with silymarin.
Biochem Pharmacol Sonnenbichler 35 538 1986 10.1016/0006-2952(86)90233-9 Stimulatory effect of Silibinin on the DNA synthesis in partially hepatectomized rat livers: non-response in hepatoma and other malignant cell lines.
J Bioenerg Biomembr Masini 32 175 2000 10.1023/A:1005512014280 Iron-induced oxidant stress leads to irreversible mitochondrial dysfunctions and fibrosis in the liver of chronic iron-dosed gerbils: the effect of silybin.
Am J Clin Pathol Reitman 28 56 1957 10.1093/ajcp/28.1.56 A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases.
Tokai J Exp Clin Med Lapis 11 suppl 135 1986 Experimental studies on the effect of hepatoprotective compounds.
Hepatology Boigk 26 643 1997 10.1002/hep.510260316 Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats.
Ann Clin Biochem Halim 34 656 1997 10.1177/000456329703400610 Biochemical effect of antioxidants on lipids and liver function in experimentally-induced liver damage.
J Clin Gastroenterol Lieber 37 336 2003 10.1097/00004836-200310000-00013 Silymarin retards the progression of alcohol-induced hepatic fibrosis in baboons.
Gastroenterol Clin Biol Trinchet 13 120 1989 Treatment of alcoholic hepatitis with silymarin: a double-blind comparative study in 116 patients.
Rev Med Chil Bunout 120 1370 1992 Controlled study of the effect of silymarin on alcoholic liver disease.
J Hepatol Pares 28 615 1998 10.1016/S0168-8278(98)80285-7 Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial.
J Hepatol Ferenci 9 105 1989 10.1016/0168-8278(89)90083-4 Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver.
Tokai J Exp Clin Med Lang 15 123 1990 Hepatoprotective and immunological effects of antioxidant drugs.
Orv Hetil Deak 131 1291 1990 Immunomodulator effect of silymarin therapy in chronic alcoholic liver diseases.
Orv Hetil Feher 130 2723 1989 Liver-protective action of silymarin therapy in chronic alcoholic liver diseases.
Med J Aust 170 218 1999 10.5694/j.1326-5377.1999.tb140322.x An adverse reaction to the herbal medication milk thistle (Silybum marianum).
Scand J Gastroenterol Salmi 17 517 1982 10.3109/00365528209182242 Effect of silymarin on chemical, functional, and morphological alterations of the liver: a double-blind controlled study.
Pharmacotherapy Piscitelli 22 551 2002 10.1592/phco.22.8.551.33205 Effect of milk thistle on the pharmacokinetics of indinavir in healthy volunteers.
Life Sci Dehmlow 58 1591 1996 10.1016/0024-3205(96)00134-8 Scavenging of reactive oxygen species and inhibition of arachidonic acid metabolism by silibinin in human cells.
Arzneimittelforschung Schandalik 42 964 1992 Pharmacokinetics of silybin in bile following administration of silipide and silymarin in cholecystectomy patients.
Cell Biochem Funct Basaga 15 27 1997 10.1002/(SICI)1099-0844(199703)15:1<27::AID-CBF714>3.0.CO;2-W Free radical scavenging and antioxidative properties of silibin complexes on microsomal lipid peroxidation.
Therapiewoche Fintelmann 30 5589 1980 Nachweis der therapeutischen Wirksamkeit von Legalon bei toxischen Lebererkrankungen im Doppelblindversuch.
Vutr Boles Brailski 25 3 43 1986 [Effect of Carsil and legalon in treating chronic liver diseases].
Z Klein Med Albrecht 47 87 1992 Die Therapie toxischer Leberschaden mit Legalon.
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.